(Total Views: 46)
Posted On: 08/05/2025 4:24:59 PM
Post# of 126
NetworkNewsBreaks – Soligenix, Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older adults—represents a promising solution. With successful domestic manufacturing of HyBryte’s active ingredient, the company advances its mission to serve this underserved demographic with innovative, U.S.-based therapies.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
